Drug Maker, Glenmark pharmaceuticals (Q, N,C,F)* announced today, November 20 that Glenmark Generics its US arm had received a final approval from US Food and Drug Administration (USFDA) to market Ranitidine Hydrochloride on prescription basis.

The said drug would be available in the tablet form in the strengths of 150 mg base and 300 mg base respectively.

Ranitidine decreases acid in the stomach to help treat an ulcer or prevent one from developing. It also helps to decrease the stomach pain, diarrhea, and loss of appetite that ulcers can cause.

Recently, the company`s US arm has initiated distribution of Morphine Sulfate oral concentrate solution, the company`s fifth product offering in the area of pain management in the US market through a licensing agreement with a US-based pharmaceutical development company.

Shares of the company declined Rs 14.3, or 4.54%, to trade at Rs 301. The total volume of shares traded was 28,576 at the BSE (10.21 a.m., Thursday).